Last reviewed · How we verify

NCT05805683

Calcitonin Therapy on Incidence and Severity of Neuropathic Pain After Spinal Cord Injury

Recruiting now NA Last updated 6 May 2025
What this trial tests

NA trial testing Calcitonin in Calcitonin in 50 participants. Currently enrolling.

Timeline
1 May 2023
Primary endpoint
1 May 2026
1 May 2027

Quick facts

Lead sponsorTanta University
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposeprevention
Enrollment50
Start date1 May 2023
Primary completion1 May 2026
Estimated completion1 May 2027
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Tanta University

Who can join

18 and older, any sex, with Calcitonin or Neuropathic Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This prospective randomized double blinded study will be conducted to evaluate the effect of early pharmacologic intervention with calcitonin on the incidence or the severity of neuropathic pain after spinal cord injury

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Calcitonin

Trials testing the same drug.

Other recruiting trials for Calcitonin

Currently open trials in the same condition.

Other Tanta University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05805683.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing